Genes and Drug Response
The same dose of the same medication can produce dramatically different effects in different people — full benefit in one, no effect in another, and dangerous toxicity in a third — largely because genetic variation affects how individuals metabolize drugs. Pharmacogenomic testing analyzes these variants to predict how a specific patient will likely respond to particular medications, moving prescribing from population averages toward individual precision.
Where Testing Changes Care
Pharmacogenomic testing has clear clinical value for several well-studied drug-gene interactions: certain blood thinners, specific chemotherapy agents, some psychiatric medications, and particular pain medications all have genetic variants that significantly affect dosing safety or efficacy. For these medications, testing before or early in treatment can prevent adverse reactions, avoid ineffective treatment trials, and guide appropriate dosing from the start rather than through trial and error.
The Expanding Role
Some health systems now perform preemptive pharmacogenomic testing, banking genetic information that can inform prescribing decisions throughout a patient lifetime as new medications are considered, rather than testing reactively for each new prescription. As evidence accumulates and testing costs decline, pharmacogenomics is gradually becoming a more routine part of how medications are selected and dosed, particularly for higher-risk drug categories. Facilities can source lab supplies and pharmacy supplies from our catalog.
